drug-induced toxicity. Since the development of monoclonal antimyosin antibody Fab by Khaw et al,7.8 "'Inlabeled antimyosin has allowed the noninvasive detection of myocardial damage in acute myocardial infarction9'10 and myocarditis,11-13 myocardial injury in cardiomyopathy,14 and rejection after heart transplantation. 15 Six-week-old male Wistar-Imamichi rats (weight, 154+15 g) were used in this study. They were allowed food and water ad libitum and were maintained under a constant room temperature and a 12-hour light-dark schedule. They were weighed each week, and their general condition was observed. The animals were divided into two groups. In the doxorubicin-treated group, the drug dissolved in 0.9% saline was administered intravenously to 20 rats at a dosage of 3 mg/kg given weekly for 5 weeks. That dosage was determined in a pilot study that showed that doxorubicin-related morphological damage and impairment of cardiac function would be induced in animals exposed to that dosage. 19 The cumulative dose of 15 mg/kg in this study was considered to be equivalent to a dose of more 500 mg. kg`m-2 in a 50-kg human. The control group consisted of 11 rats that received an equal volume of 0.9% saline administered intravenously each week for the same period. Three weeks after the final injection of doxorubicin,`11In antimyosin was injected intravenously in control and doxorubicin-treated rats, and they were killed 48 hours later. In addition, a separate study was conducted with`M51-labeled monoclonal anti-IgG Fab antibody to determine whether the antimyosin antibody was specific to doxorubicin-induced damaged myocardium. 1251 anti-IgG antibody was injected intravenously in 10 control and 10 doxorubicin-treated rats, and they were also treated in the same manner as described above.
Hemodynamic Measurements
At week 7 of the experiment, baseline hemodynamics were assessed after the administration of sodium pentobarbital (50 mg/kg i.p.). The right jugular vein was cannulated with a polyethylene catheter connected to a Statham transducer (P1OEZ, Gould, Inc., Cleveland, Ohio). The catheter was advanced into the right ventricle. The external right carotid artery was exposed and cannulated with a micromanometer-tipped catheter (PR249, Millar Instruments, Houston, Tex.). Measurements were thus obtained of both the ventricular systolic and end-diastolic pressures and positive dP/dt of the left ventricle, aortic pressure, and heart rate by ECG monitoring.
Morphological Studies
After cardiac catheterization, the rats were killed by exsanguination. The heart and skeletal muscle were excised and fixed in 10% buffered formalin for histological study. Paraffin-embedded sections 4 ,um thick were trichrome stain, and mounted. For ultrastructural exam- 100). In addition, heartto-blood ratios and heart-to-lung ratios of`'In antimyosin antibody were calculated from tissue uptake.
Immunoautoradiography of Heart
Each animal was injected intravenously with 3.7 MBq (100 ,uCi) of`'In antimyosin antibody and killed 48 hours later. Transverse sections of the excised heart filled with carboxymethyl cellulose gel were quickly frozen by immersion in acetone and dry ice at -80°C. The frozen heart sections were cut on a cryomicrotome (NA 200, Nakagawa, Tokyo) at -20°C into 20-,um-thick sections. These sections were placed onto an imaging plate (20 x 40 cm) with a resolution of 10 pixels/mm (Fujix Bio-imaging Analyzer BAS2000, Fuji Photo Film Co., Ltd., Tokyo)20 for 1 hour of exposure time. The dose of radioactivity in the heart sections was quantified promptly on the cathode ray tube screen and was printed in color. For a histological autoradiography, cardiac specimens were fixed in periodate-lysine-paraformaldehyde fixative (0.01 M sodium metaperiodic acid, 0.075 M lysine monohydrochloride, 2% paraformaldehyde, 0.0375 M phosphate buffer) for 6 hours at 4°C and quickly frozen in optimum cutting temperature compound (Miles Scientific, Elkhart, Ind.) cooled in liquid nitrogen. Cryostat sections at 2 ,gm were thawmounted on albumin-coated slides. The slides were dipped in Konika NR-M2 emulsion (Konika Corp., Tokyo) diluted 1:1.5 with water at 43°C, dried for 30 minutes, and stored in light-tight boxes at 4°C. After 6-8 weeks' exposure, the slides were developed in Konidol X developer (Konika Corp., Tokyo), rinsed in 0.1 M acetic acid, fixed in Konifix (Konika Corp., cut, stained with hematoxylin and eosin and Masson's Tokyo), and stained with hematoxylin-eosin. Sections 
Results

Baseline Hemodynamics
Of the 20 rats given doxorubicin, six died during the experiment of congestive heart failure, and the remaining 14 developed pleural effusion, pericardial effusion, and ascites associated with heart failure. Significant weight loss was observed in the doxorubicin-treated rats compared with controls (Table 1 ). The ratio of heart to body weight was markedly increased in the drug-treated animals, suggesting myocardial hypertrophy. In the treated rats, both left and right ventricular end-diastolic pressures were significantly increased, whereas the systolic left ventricular and mean aortic pressures were decreased. A substantial decrease in positive dP/dt of the left ventricle was also evident in the treated rats, indicating a global impairment of left ventricular function.
Morphological Studies
On global examination of the heart, left and right ventricular dilatation was observed. Variable myocardial damage occurred with focal changes (Figure 1 Tissue Distribution Studies Table 2 summarizes the concentrations of 1"'in antimyosin in the blood, heart, lung, liver, skeletal muscle, and sternum of the treated versus control rats. The myocardial uptake of radioactivity was significantly increased in the drug-treated animals compared with the control group (p<0.001). The left ventricular uptake of the tracer was significantly higher than that of the right ventricle (p<0.001) in all doxorubicin-treated rats. In contrast, there was a significantly lower uptake of radioactivity in the blood, muscle, and sternum of the treated rats (p<0.001). No differences in the uptake of radioactivity in liver and lung were noted between the treated and control groups. A summary of the concentration ratios of 1"'In antimyosin for heart to blood and heart to lung appears in Table 3 . The ratios of left and right ventricles to blood in the doxorubicin-treated rats were 15-fold and 10-fold, respectively, significantly higher than the control values (p<0.001). Similar results were observed with the heart-to-lung concentration ratios of the doxorubicin-treated rats (p<0.01). On the other hand, there was little tissue difference of 1251 anti-IgG antibody uptake between the doxorubicintreated and control rats in Table 4 , suggesting that specificity is associated with the use of the antimyosin antibody and that the myocardial uptake of the radiolabeled antibody is not from permeability in the injured myocardium.
Myocardial Uptake Versus Morphological Changes Figure 2 shows the mean ventricular uptake of "In 
Myocardial Uptake Versus Hemodynamics
As shown in Figure 3 , the myocardial uptake of "'In antimyosin was strongly correlated with the left ventricular end-diastolic pressure (r=0.84, p<0.001) and the right ventricular end-diastolic pressure (r=0.83, p<0.001) in the doxorubicin-treated rats. There was little correlation of uptake of tracer with the dP/dt and systolic pressure of the left ventricle and the mean aortic pressure. Immunoautoradiography of the Heart Figure 4 shows representative autoradiograms for the control and doxorubicin-treated rats. An increased cardiac uptake of 11In antimyosin was clearly evident as the severity of myocardial damage increased. On microscopic autoradiography (Figure 5) been used to detect the cardiomyocyte injury accompanying acute myocardial infarction. 24 Myocardial damage has been assessed by Chacko et al,25 who reported that the uptake of pyrophosphate was distributed diffusely throughout the myocardium of nine of 15 patients (60%) with various malignant neoplasms undergoing doxorubicin treatment and also, in some cases, mediastinal irradiation.
Recently, the immunoscintigraphic agent`'In monoclonal antimyosin antibody Fab been developed for imaging the myocardial damage in vivo.9-11,13-16 This radiolabeled antimyosin has been shown to bind specifically to intracellular myosin when sarcolemmal disruption of cardiac myocytes occurs and the cell is damaged irreversibly.26 Suggestions for the underlying mechanism of doxorubicin cardiotoxicity include the oxidation of cell membrane by free radicals,27 inhibition of mitochondrial enzymes,28 reduced synthesis of DNA,29 formation of a toxic metabolite of doxorubicin,30 and selective disturbance of muscle gene expression in cardiomyocytes.31 These factors may be responsible for the mitochondrial degeneration, myofibrillar loss, distended sarcotubular systems, and vacuolation of the sarcoplasmic reticulum observed in our study. We clearly demonstrated a specific myocardial localization of the antimyosin antibody in rats administered doxorubicin by immunoautoradiography of the heart, indicating that the monoclonal antibody specific for human myosin heavy chains (R11D10) has high affinity for rat ventricular myosin. A more intense myocardial (80%) ; eight of the 20 (40%) with impaired cardiac function presented with a more intense uptake of antimyosin. However, the relation between the extent of cardiac uptake of the tracer and the morphological changes in the heart was not examined. The present study in rats shows that as the severity of myocyte damage increases, there is a corresponding significant increase in antimyosin uptake. Also, there was a strong correlation between antimyosin uptake and both ventricular end-diastolic pressures in rats. An increased ventricular end-diastolic pressure reflects an alteration in the ventricular pressure-volume relation or a decrease in diastolic compliance of the ventricle.36 In this rat model, an increment in end-diastolic pressure may occur with a failure of the dilated ventricles caused by doxorubicin-induced myocardial damage, resulting in a good correlation with the antimyosin uptake. But Inser et a132 had found that seven (35%) of 20 patients with anthracycline cardiotoxicity showed no specific histological signs. Moreover, histopathological abnormalities had been found in 23 (52%) of patients without clinical toxicity, even at lower doses.
In the present study, there was a more definite correlation between the two parameters. The possible reasons for the discrepancies may include that we evaluated morphological findings in the large section of the heart instead of focal myocardial biopsy by both light and electron microscopies and that the cumulative dose of doxorubicin was very large to produce injury of the myocytes followed by congestive heart failure in all rats. On the contrary, there was little correlation between the left ventricular dP/dt and the degree of histological damage or the`11In antimyosin uptake in the left ventricle. The possible explanation for the result may be that the positive dP/dt as one of the isovolumetric phase indexes is usually of little value in assessing this property of cardiac function, as are the ejection phase indexes, and in classifying contractility among different patients. 37 Control Lox FIGURE 4. Color autoradiography of the excised heart in control (left) and in doxorubicin-treated rats (middle and right) after administration of "'In antimyosin antibody, 3.7 MBq. A higher luptake of radioactivity in the heart is indicated by the red color and a lower dose by the blue color. The autoradiogram of the doxorubicin-treated heart in the middle picture shows worse myocardial damage than that in the right. DOX doxoruibicin-treated rat. The limitations of this study are as follows. Our experiment reported preliminarily the usefulness of`t1In antimyosin antibody for detecting the myocardial damage induced by doxorubicin in comparison with its hemodynamic effects. The cumulative dose of doxorubicin used in this study (15 mg/kg) was enough to induce morphological changes in the rat heart similar to the results reported by Jensen et al. 38 From the clinical point of view, it is important to develop a means for the early detection of cardiac toxicity. Therefore, the relation between antimyosin uptake and the dose-dependent damage to the myocytes remains to be completely defined.
In conclusion,`11In antimyosin antibody appears to be a valuable radiopharmaceutical agent in detecting early cardiac damage and in evaluating the severity of the doxorubicin-induced cardiotoxicity. Furthermore, myocardial imaging using the radiotracer is noninvasive, and it can provide information to guide the course of doxorubicin treatment in patients without other evidence of myocardial damage.
